| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: NWBT |
| Security Type |
Common Stock |
| Lead Underwriter |
CE Unterberg Towbin |
| Days In Registration |
123 |
| Date Filed |
13-Aug-2001 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2007) |
| Industry |
Manufacturing |
| Business Description |
Discover, develop, and commercialize immunotherapy products that generate and enhance immune system responses to effectively treat cancer |
| Revenue |
$0.1M |
| Net Income |
-$10.9M |
| Shares Outstanding (post-offering) |
16.35M |
| Chairman, President & CEO |
Daniel O. Wilds |
| Number of Employees |
51 |
|
| Original Filing Information |
| US |
| Shares Filed |
- |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
- |
| · As a Percent |
- |
| Overallotment Shares Filed |
600.0K |
| File Amount |
- |
| File Price Range |
$11.00 - $9.00 |
| File Mid Price |
$10.00 |
Current Filing Information
(Amended 14-Dec-2001) |
|
US |
|
Shares Filed |
4.0M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
4.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$22.0M |
| · % Change from Original |
|
| File Price Range |
$6.00 - $5.00 |
| File Mid Price |
$5.50 |
|
